CREATE Medicines
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
$122MSeries B
Role not disclosedAV
Alexandria Venture Investments
Activity from announced rounds
Activity in this selectionUnited States · May 31, 2026 · May 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $122M 1 disclosed · full round size, not this investor’s share